Satoshi Fukasawa

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 679 citations · Full text

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George et al. · Cancer · 2020 · 327 citations · Full text

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

Pretreatment Serum Testosterone Level as a Predictive Factor of Pathological Stage in Localized Prostate Cancer Patients Treated with Radical Prostatectomy

Takashi Imamoto, Hiroyoshi Suzuki, Satoshi Fukasawa et al. · European Urology · 2004 · 119 citations

Urology, Predictive Factor, Genitourinary Cancer +6